Group 1 - The core viewpoint of the news is that Sihuan Pharmaceutical (00460.HK) has had its MSCI ESG rating upgraded from BBB to A as of March 13, 2026, indicating an improvement in its ESG performance [1][3]. - The Sina Finance ESG Rating Center offers 14 ESG services, including information, reports, training, and consulting, aimed at helping listed companies promote ESG concepts and enhance their sustainable development performance [1][3]. Group 2 - The Sina Finance ESG Rating Center is the first Chinese professional information and rating aggregation platform for ESG, dedicated to promoting sustainable development and responsible investment, as well as the values of ESG (Environmental, Social, and Governance) [2][4]. - The center aims to establish ESG evaluation standards suitable for China's characteristics and promote the development of ESG investment in the Chinese asset management industry [2][4].

四环医药：本集团旗下非全资附属公司轩竹生物被调入沪港通与深港通下港股通标的名单。 来源：滚动播报 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 自願公告 軒竹生物股份納入港股通股票名單 四 環 醫 藥 控 股 集 團 有 限 公 司（「本公司」或「四環醫藥」，連 同 其 附 屬 公 司，統 稱 為 「本集團」）董 事 會（「董事會」）欣 然 宣 佈，根 據 上 海 證 券 交 易 所 及 深 圳 證 券 交 易 所 於 二 零 二 六 年 三 月 六 日 分 別 發 佈 的《關 於 滬 港 通 下 港 股 通 標 的 調 整 的 通 知》、 《關 於 深 港 通 下 的 港 股 通 標 的 證 券 名 單 調 整 的 公 告》，本 集 團 旗 下 非 全 資 附 屬 公 司 軒 竹 生 物 科 技 股 份 有 限 公 司（「軒 ...

消息面上，3月3日，四环医药发布公告，集团旗下非全资附属公司轩竹生物科技股份有限公司自主研发 的创新药吡洛西利片(商品名：轩悦宁®)联合芳香化酶抑制剂(AI)一线治疗激素受体阳性(HR+)、人表皮 生长因子受体2阴性(HER2-)(HR+/HER2-)晚期乳腺癌的新适应症上市申请(sNDA)，已获得中国国家药品 监督管理局(NMPA)批准上市。 这是吡洛西利继联合氟维司群、单药治疗适应症获批后，在中国获批的第三个适应症，至此吡洛西利成 为中国首个且唯一覆盖HR+/HER2-晚期乳腺癌一线、二线、后线全疗程的同类药物。吡洛西利获批适 应症扩展至HR+/HER2-晚期乳腺癌一线治疗，显著扩大了患者覆盖范围，有效提升了产品的临床价值 与药物可及性，为其后续销售规模增长提供了有力支撑。 四环医药(00460)午前涨超5%，截至发稿，涨5.19%，报1.42港元，成交额1946.91万港元。 ...

Core Viewpoint - Four Ring Pharmaceutical (00460) experienced a stock increase of over 5%, reaching 1.42 HKD, following the approval of a new indication for its innovative drug, Pyrotinib (brand name: XuanYueNing), for the first-line treatment of HR+/HER2- advanced breast cancer in China [1] Group 1 - The company announced that its subsidiary, XuanZhu Biotechnology Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the supplemental new drug application (sNDA) of Pyrotinib [1] - This approval marks the third indication for Pyrotinib in China, following its previous approvals for combination therapy with Fulvestrant and monotherapy [1] - Pyrotinib is now the first and only drug in China to cover the entire treatment course for HR+/HER2- advanced breast cancer across first-line, second-line, and later lines of therapy, significantly expanding patient coverage and enhancing clinical value [1]

Core Viewpoint - Four Seasons Pharmaceutical (00460) has seen its stock price increase by over 5% following the approval of its innovative drug, Pyrotinib tablets (brand name: XuanYueNing), for a new indication in the treatment of HR+/HER2- advanced breast cancer in China [1] Group 1: Company Developments - On March 3, Four Seasons Pharmaceutical announced that its subsidiary, XuanZhu Biotechnology Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the new indication of Pyrotinib tablets in combination with aromatase inhibitors for first-line treatment of HR+/HER2- advanced breast cancer [1] - This approval marks the third indication for Pyrotinib in China, following its previous approvals for use in combination with Fulvestrant and as a monotherapy [1] - Pyrotinib is now the first and only drug in China to cover the entire treatment course for HR+/HER2- advanced breast cancer across first-line, second-line, and later lines, significantly expanding patient coverage and enhancing clinical value [1] Group 2: Market Impact - The approval is expected to effectively increase the drug's accessibility and clinical value, providing strong support for future sales growth [1] - As of the report, Four Seasons Pharmaceutical's stock price rose by 5.19%, reaching HKD 1.42, with a trading volume of HKD 19.4691 million [1]

Core Viewpoint - The approval of the new indication for Pyrotinib (brand name: XuanYueNing) for first-line treatment of HR+/HER2- advanced breast cancer significantly enhances its clinical value and accessibility, supporting future sales growth for the company [1]. Company Summary - Four Seasons Pharmaceutical (00460) announced that its subsidiary, XuanZhu Biotechnology Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the new indication of Pyrotinib in combination with aromatase inhibitors for first-line treatment of HR+/HER2- advanced breast cancer [1]. - This marks the third approved indication for Pyrotinib in China, making it the first and only drug in the country to cover the entire treatment course for HR+/HER2- advanced breast cancer across first, second, and later lines [1]. Industry Summary - Breast cancer is the most commonly diagnosed malignant tumor among women globally, with new cases in China projected to rise from 322,200 in 2018 to 374,700 in 2024, and expected to reach 435,000 by 2032 [2]. - HR+/HER2- breast cancer is the most prevalent subtype in China, accounting for approximately 75% of total cases, with about 30% of these patients diagnosed with advanced breast cancer [2]. - The market for CDK4/6 inhibitors combined with endocrine therapy for HR+/HER2- advanced breast cancer in China is expected to reach RMB 13 billion by 2032 [2]. Clinical Research Summary - The approval of the new indication is based on data from the BRIGHT-3 study (NCT05257395), a randomized, double-blind Phase III clinical trial conducted at 58 centers in China [3]. - The study aimed to evaluate the efficacy and safety of Pyrotinib in combination with Letrozole or Anastrozole for first-line treatment of HR+/HER2- advanced breast cancer [3]. - Results indicated that the median progression-free survival (mPFS) for the Pyrotinib group has not yet been reached, while the control group reported mPFS of 18.43 months and 19.55 months, suggesting a durable efficacy advantage for Pyrotinib [3]. - The Pyrotinib regimen reduced the risk of disease progression or death by 47% compared to the placebo combined with endocrine therapy, with a notable 64% reduction in patients with liver metastases [3]. - The overall response rate (ORR) in the intention-to-treat population for the Pyrotinib group was 63.5%, significantly higher than the control group's 42.5% [3]. - Common adverse events associated with the Pyrotinib regimen were mostly grade 1-2 and manageable through supportive care or dose adjustments, indicating an overall controllable safety profile [3].

Core Viewpoint - The approval of the new indication for Pyrotinib (brand name: XuanYueNing®) as a first-line treatment for HR+/HER2- advanced breast cancer significantly enhances its clinical value and accessibility, supporting future sales growth for the company [1]. Group 1: Company Developments - Four Ring Pharmaceutical (00460) announced that its subsidiary, XuanZhu Biotechnology Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the new indication of Pyrotinib in combination with aromatase inhibitors for HR+/HER2- advanced breast cancer [1]. - Pyrotinib is now the first and only drug in China to cover the entire treatment course for HR+/HER2- advanced breast cancer across first-line, second-line, and subsequent lines [1]. Group 2: Market Context - Breast cancer is the most commonly diagnosed malignant tumor among women globally, with new cases in China projected to rise from 322,200 in 2018 to 374,700 in 2024, and expected to reach 435,000 by 2032 [2]. - HR+/HER2- breast cancer accounts for approximately 75% of total cases in China, with about 30% of these patients diagnosed with advanced breast cancer [2]. - The market for CDK4/6 inhibitors in China is expected to reach RMB 13 billion by 2032, as these inhibitors combined with endocrine therapy have become the standard first-line treatment for HR+/HER2- advanced breast cancer [2]. Group 3: Clinical Research Insights - The approval of the new indication is based on data from the BRIGHT-3 study, a randomized, double-blind Phase III clinical trial conducted at 58 centers in China [3]. - The BRIGHT-3 study results indicated that the median progression-free survival (mPFS) for the Pyrotinib group has not yet been reached, while the control group reported mPFS of 18.43 months and 19.55 months, suggesting a durable efficacy advantage for Pyrotinib [3]. - Pyrotinib treatment reduced the risk of disease progression or death by 47% compared to placebo, with a notable 64% reduction in patients with liver metastases, highlighting its potential in difficult-to-treat populations [3]. - The overall response rate (ORR) for the Pyrotinib group was 63.5%, significantly higher than the control group's 42.5% [3]. - Common adverse events associated with the Pyrotinib regimen were mostly grade 1-2 and manageable through supportive care or dose adjustments, indicating an overall controllable safety profile [3].

Core Viewpoint - Four Ring Pharmaceutical's subsidiary, Xuan Bamboo Biotechnology, has received approval from the NMPA for the new indication of Pyrotinib tablets (brand name: Xuan Yuening®) for first-line treatment of HR+/HER2- advanced breast cancer, marking it as the first and only drug in China to cover all treatment lines for this condition [1][4]. Group 1: Company Developments - The approval of Pyrotinib's new indication significantly expands the patient coverage and enhances the clinical value and accessibility of the drug, providing strong support for future sales growth [1]. - Pyrotinib has now been approved for three indications in China, following its previous approvals for combination therapy with Fulvestrant and monotherapy [1]. Group 2: Industry Context - Breast cancer is the most commonly diagnosed malignant tumor among women globally, with new cases in China projected to rise from 322,200 in 2018 to 374,700 in 2024, and expected to reach 435,000 by 2032 [2]. - HR+/HER2- breast cancer is the most prevalent subtype in China, accounting for approximately 75% of cases, with about 30% of these diagnosed as advanced [2]. - The market for CDK4/6 inhibitors combined with endocrine therapy for HR+/HER2- advanced breast cancer is expected to reach RMB 13 billion by 2032 [2]. Group 3: Clinical Research Insights - The approval for the new indication is based on data from the BRIGHT-3 study, a randomized, double-blind Phase III clinical trial conducted at 58 centers in China, assessing the efficacy and safety of Pyrotinib in combination with Letrozole or Anastrozole [3]. - The study results indicated that the median progression-free survival (mPFS) for the Pyrotinib group has not yet been reached, suggesting a durable efficacy advantage, with a 47% reduction in the risk of disease progression or death compared to the control group [3]. - In the intention-to-treat population, the overall response rate (ORR) for the Pyrotinib group was 63.5%, significantly higher than the control group's 42.5%, with manageable safety profiles for common adverse events [3].

Core Viewpoint - The approval of the new indication for Pyrotinib (brand name: XuanYueNing) as a first-line treatment for HR+/HER2- advanced breast cancer significantly enhances its clinical value and accessibility, supporting future sales growth for the company [1]. Group 1: Company Developments - Four Ring Pharmaceutical (00460) announced that its subsidiary, XuanZhu Biotechnology Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the new indication of Pyrotinib in combination with aromatase inhibitors for HR+/HER2- advanced breast cancer [1]. - Pyrotinib is now the first and only drug in China to cover the entire treatment course for HR+/HER2- advanced breast cancer across first-line, second-line, and subsequent lines [1]. Group 2: Market Context - Breast cancer is the most commonly diagnosed malignant tumor among women globally, with new cases in China projected to rise from 322,200 in 2018 to 374,700 in 2024, and expected to reach 435,000 by 2032 [2]. - HR+/HER2- breast cancer accounts for approximately 75% of cases in China, with about 30% of these patients diagnosed at an advanced stage [2]. - The market for CDK4/6 inhibitors combined with endocrine therapy for HR+/HER2- advanced breast cancer in China is expected to reach RMB 13 billion by 2032 [2]. Group 3: Clinical Research Insights - The approval for the new indication is based on data from the BRIGHT-3 study, a randomized, double-blind Phase III clinical trial conducted at 58 centers in China [3]. - The BRIGHT-3 study results indicated that the median progression-free survival (mPFS) for the Pyrotinib group has not yet been reached, while the control group reported mPFS of 18.43 months and 19.55 months [3]. - Pyrotinib demonstrated a 47% reduction in the risk of disease progression or death compared to the control, with a notable 64% reduction in patients with liver metastases [3]. - The overall response rate (ORR) for the Pyrotinib group was 63.5%, significantly higher than the control group's 42.5% [3]. - Common adverse events associated with the Pyrotinib regimen were manageable and primarily of grade 1-2 severity, indicating an overall controllable safety profile [3].